Vertex Pharmaceuticals' SWOT analysis: cystic fibrosis leader faces pipeline challenges
Vertex Pharmaceuticals (NASDAQ:VRTX), a global biotechnology company with a market capitalization of $119.1 billion known for its transformative cystic fibrosis (CF) treatments, finds itself at a ...
Hosted on MSN1d
FDA Approves New Non-Opioid Painkiller for Acute Pain-What to Know!
A massive stride has been made in the pain medication industry. The U.S. Food and Drug Administration (FDA) announced Thursday its approval of a non-opioid treatment for moderate to severe acute pain ...
Discover Magazine1d
FDA Approves Opioid Alternative for Pain Relief That Is Non-Addictive
Because the drug doesn’t target the brain, it has less potential for addiction. Learn why this could help the opioid crisis.
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...
Scientific American1d
What Is Journavx, the New Opioid-Free Painkiller from Vertex?
The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...
New sickle cell treatment approved for NHS use offers patients ‘hope of a cure’
One sickle cell patient told ITV News the new gene therapy being rolled out for use on the NHS means they "finally have something to look towards". | ITV National News ...
VRTX Gets FDA Nod for Non-Opioid Pain Drug Journavx, Shares Up
The FDA approves Vertex's non-opioid oral pain signal inhibitor, Journavx, for treating adults with moderate-to-severe acute pain. Shares rise.
Vertex Pharmaceuticals Incorporated Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VRTX
NEW YORK, NY / ACCESS Newswire / January 31, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
PMLiVE1d
NICE approves Vertex’s Casgevy one-time gene therapy for sickle cell disease
The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...
The Bakersfield Californian2d
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England
Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY ...
Courthouse News Service2d
FDA approves painkiller designed to eliminate the risk of addiction associated with opioids
The new drug will carry a list price of $15.50 per pill, making it many times more expensive than comparable opioids.
Vertex Pharmaceuticals’ non-opioid Journavx approved for pain by FDA
Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class ...